GSK (GSK) Competitors

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.

Is NVS or GSK more profitable?

Novartis has a net margin of 35.96% compared to GSK's net margin of 7.97%. GSK's return on equity of 50.62% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	35.96%	34.80%	15.13%
GSK	7.97%	50.62%	11.54%

Does the media refer more to NVS or GSK?

In the previous week, Novartis had 5 more articles in the media than GSK. MarketBeat recorded 23 mentions for Novartis and 18 mentions for GSK. Novartis' average media sentiment score of 0.94 beat GSK's score of 0.12 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of NVS or GSK?

13.1% of Novartis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts rate NVS or GSK?

Novartis currently has a consensus target price of $121.50, indicating a potential upside of 17.89%. GSK has a consensus target price of $43.25, indicating a potential upside of 29.69%. Given GSK's stronger consensus rating and higher possible upside, analysts plainly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60

Does the MarketBeat Community believe in NVS or GSK?

GSK received 285 more outperform votes than Novartis when rated by MarketBeat users. However, 61.09% of users gave Novartis an outperform vote while only 56.92% of users gave GSK an outperform vote.

Company	Underperform	Outperform
Novartis	Outperform Votes 529 61.09%	Underperform Votes 337 38.91%
GSK	Outperform Votes 814 56.92%	Underperform Votes 616 43.08%

Which has more risk & volatility, NVS or GSK?

Novartis has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Is NVS or GSK a better dividend stock?

Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.4%. GSK pays an annual dividend of $1.54 per share and has a dividend yield of 4.6%. Novartis pays out 28.2% of its earnings in the form of a dividend. GSK pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has better earnings & valuation, NVS or GSK?

Novartis has higher revenue and earnings than GSK. Novartis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$45.44B	4.64	$14.85B	$8.61	11.97
GSK	$37.71B	1.83	$6.13B	$1.54	21.66

Summary

Novartis and GSK tied by winning 10 of the 20 factors compared between the two stocks.